Cervical Cancer Clinical Trial
Official title:
Observational Study for Determine the Presence and Genotypes of HVP Infection in Cervical Intraepithelial Neoplasia Grade II-III (CIN II-III), and Stage I Cervical Epidermoid Carcinoma and Cervical Adenocarcinoma.
1. Hypothesis:
If high risk genotypes of human papillomavirus (HPV) is the cause of cervical cancer
worldwide, the genotypes associated with cervical cancer in Venezuela would be the same
types found in other countries.
2. Objectives:
Primary objective:
The objective of this investigation is to determine the presence and genotypes of HVP
infection in cervical intraepithelial neoplasia grade 2/3 (CIN 2/3), and Stage I cervical
epidermoid carcinoma and cervical adenocarcinoma.
Specific objectives:
To establish the presence of HPV in cervical cancer patients in Venezuela by geographic
distribution.
To establish which HPV types are linked with cervical cancer in Venezuela by geographic
distribution.
In Venezuela, cervical cancer is the second leading cause of cancer mortality in women. In
developed countries, although it is not the first cause of cancer mortality, occupies a
remarkable place in the neoplastic pathology (Cannistra, 1996; Dey, 1998).
Human Papilloma Virus (HPV) is involved in the development of cervical cancer, specially
oncogenic types 16 and 18 (Koskela, 2000; Markowska, 1999).
To date, it is still unknown which HPV types are more frequent in Venezuela. Several studies
made in this country concluded that HPV 16 is the predominant type in cervical pathology
(Graterol 2006, Correnti 1997, Muñoz 2003), but there has not been performed a HVP
genotyping to detect all the types involved in patients with cervical cancer. Neither has
been establish which HPV types are more frequently involved in genital warts in Venezuela.
The goal of this investigation is perform a genotypification of HPV in cervical cancer and
cervical intraepithelial neoplasia 2 and 3 in Venezuela to determine which types are more
frequently related to this disease in our country.
4. STUDY DESIGN:
4.1. Collection of cervical samples:
1. Previous ethics committee approval (Instituto Venezolano de Investigaciones Cientificas
and Instituto de Oncología Luis Razetti), we are going to collect paraffin blocks of 300
patients with histological diagnosis of CIN 2-3 or Stage I cervical cancer.
The samples will be obtained from archives of the Pathology Units of the following medical
centers in Venezuela: Instituto de Oncología Luis Razetti, Anatomía Patológica Universidad
Central de Venezuela(Caracas), Hospital Oncológico Pérez Carreño (Valencia), Maracaibo,
Barquisimeto, Ciudad Bolívar, Puerto La Cruz, Mérida and Barinas.
Inclusion criteria:
1. Paraffin blocks with CIN 2/3, and Stage I cervical cancer biopsies obtained between
2001 and 2011.
2. Properly blocks identification in order to obtain personal and clinical patient
information.
4.2. Molecular biology procedures:
1. Histologically handling of tissue: previous identification of pathologic lesions as
described in inclusion criteria by an expert pathologist (sample with lesion but
without necrosis), the paraffin block will be cut into 5 to 7 µm slides with new blades
and gloves for each cut. It will be obtain 1 slides that will be distributed as
follows: one sample will be send to Laboratorio de Virología Molecular del Instituto
Venezolano de Investigaciones Científicas; the remained sample will be kept for further
evaluation if is necessary. Each slide will be placed in a proper container and will be
identified by a serial number in order to preserve patient intimacy and avoid biased
results.
2. Deparaffinisation as described in Coombs 1999.
3. Tissue digestion, DNA extraction and precipitation as described in Gravitt 2000.
4. HPV genotyping will be detected by INNOLiPA system. The results will be correlated with
clinical information.
;
Time Perspective: Prospective
Status | Clinical Trial | Phase | |
---|---|---|---|
Recruiting |
NCT06223308 -
A Study Evaluating the Safety and Efficacy of HB0028 in Subjects With Advanced Solid Tumors
|
Phase 1/Phase 2 | |
Terminated |
NCT03367871 -
Combination Pembrolizumab, Chemotherapy and Bevacizumab in Patients With Cervical Cancer
|
Phase 2 | |
Active, not recruiting |
NCT04537156 -
Efficacy, Immunogenicity and Safty Study of Recombinant Human Papillomavirus Vaccine(6,11,16,18,31,33,45,52,58 Type)(E.Coli)
|
Phase 3 | |
Recruiting |
NCT03668639 -
Safety and Antiemetic Efficacy of Akynzeo Plus Dexamethasone During Radiotherapy and Concomitant Weekly Cisplatin
|
Phase 2/Phase 3 | |
Active, not recruiting |
NCT04242199 -
Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of INCB099280 in Participants With Advanced Solid Tumors
|
Phase 1 | |
Withdrawn |
NCT04806945 -
A Phase III Study to Evaluate Efficacy and Safety of First-Line Treatment With HLX10 + Chemotherapy in Patients With Advanced Cervical Cancer
|
Phase 3 | |
Active, not recruiting |
NCT04185389 -
Long-Term Follow-Up of HPV FOCAL Participants
|
||
Withdrawn |
NCT03007771 -
Magnetic Resonance-guided High-Intensity Focused Ultrasound (MR-HIFU) Used for Mild Hyperthermia
|
Phase 1 | |
Completed |
NCT03384511 -
The Use of 18F-ALF-NOTA-PRGD2 PET/CT Scan to Predict the Efficacy and Adverse Events of Apatinib in Malignancies.
|
Phase 4 | |
Recruiting |
NCT05107674 -
A Study of NX-1607 in Adults With Advanced Malignancies
|
Phase 1 | |
Completed |
NCT05120167 -
Strategies for Endocervical Canal Investigation in Women With Abnormal Screening Cytology and Negative Colposcopy
|
N/A | |
Recruiting |
NCT05483491 -
KK-LC-1 TCR-T Cell Therapy for Gastric, Breast, Cervical, and Lung Cancer
|
Phase 1 | |
Recruiting |
NCT05736588 -
Elimisha HPV (Human Papillomavirus)
|
N/A | |
Completed |
NCT05862844 -
Promise Women Project
|
N/A | |
Recruiting |
NCT04934982 -
Laparoscopic or Abdominal Radical Hysterectomy for Cervical Cancer(Stage IA1 With LVSI, IA2)
|
N/A | |
Recruiting |
NCT03876860 -
An Enhanced Vaginal Dilator to Reduce Radiation-Induced Vaginal Stenosis
|
N/A | |
Completed |
NCT03652077 -
A Safety and Tolerability Study of INCAGN02390 in Select Advanced Malignancies
|
Phase 1 | |
Completed |
NCT00543543 -
Broad Spectrum HPV (Human Papillomavirus) Vaccine Study in 16-to 26-Year-Old Women (V503-001)
|
Phase 3 | |
Terminated |
NCT04864782 -
QL1604 Plus Chemotherapy in Subjects With Stage IVB, Recurrent, or Metastatic Cervical Cancer
|
Phase 2/Phase 3 | |
Recruiting |
NCT04226313 -
Self-sampling for Non-attenders to Cervical Cancer Screening
|
N/A |